Is global elimination of <scp>HCV</scp> realistic?

Calvaruso, Vincenza; Petta, Salvatore

doi:10.1111/liv.13668

Cited by 40 publications

(28 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV vaccination programmes have been widely implemented in countries around the globe, and eradication of HCV through the use of direct-acting antivirals is a target in many others. 61,62 While virally induced tumours will soon become less frequent, alcoholrelated cirrhosis is a stably prevalent pre-neoplastic condition, and chronic fatty liver disease associated with metabolic syndrome is a growing cause of HCC even in the absence of cirrhosis. 63 All these changes will have an impact on surveillance policies that Singal et al review nicely in this special issue.…”

Section: Pathogenesis Of Hepatocellular Carcinomamentioning

confidence: 99%

Milestones in the pathogenesis and management of primary liver cancer

Nault

Cheng

Sangro

et al. 2020

Journal of Hepatology

View full text Add to dashboard Cite

Liver cancer is a major global health problem whose incidence is on the rise. The improvement in the understanding of the pathogenesis, early detection, diagnosis, staging and treatment of liver cancer has been enormous. The landscape of molecular aberrations driving both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) have been unravelled. Several breakthroughs have occurred in the prevention, surveillance and treatment of HCC. Particularly, management of patients at advanced stages has changed dramatically during the last decade with the advent of effective systemic therapies such as sorafenib, lenvatinib, regorafenib, cabozantinib and ramucirumab. iCCA has long been considered a difficult to treat disease with few therapeutic options. However, recent advances in our understanding of its molecular pathogenesis, as well as the development of adjuvant therapy (capecitabine) and new systemic treatments (gemcitabine and cisplatin) have paved the way for further innovations in the management of patients with iCCA. In this manuscript, we aimed to highlight the main milestones in the medical history of primary liver cancer and report the most recent developments described within this special issue.

show abstract

Section: Pathogenesis Of Hepatocellular Carcinomamentioning

confidence: 99%

Milestones in the pathogenesis and management of primary liver cancer

Nault

Cheng

Sangro

et al. 2020

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…However, direct-acting antiviral drugs (DAAs) represent a vast improvement on earlier treatment regimens and offer cure rates upwards of 100% [24]. The current barriers to treatment for HCV with DAAs are primarily around cost and access [25], especially among people who use drugs [26]. …”

Section: Epidemiology Of Rural Opioid Epidemicmentioning

confidence: 99%

Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment

et al. 2018

View full text Add to dashboard Cite

Purpose of review: To describe the epidemiology opioid use disorder in the rural United States as it pertains to HIV and hepatitis C transmission and treatment resources. Recent findings: Heroin and fentanyl analouges have surpassed prescription opioids in their availability in rural opioid markets adding to HIV and hepatitis C (HCV) and overdose risks. Only 18% of rural individuals live in towns with inpatient services which are of limited quality and utiity. Opioid treatment programs that provide methadone are not located in rural areas and only 3% of the primary care providers have the ability to prescribe buprenorphine. National models and resources have been established but lack implementation in rural areas leading to ongoing HIV and HCV transmission and overdose. Summary: Addressing the adverse impact of opioids in the rural U.S. will require a concerted effort to implement effective treatments according to national standards.

show abstract

“…Moreover, a recent review by Calcvaruso et al evaluated whether global elimination of HCV is a realistic goal . They concluded that the differences in the prevalence of HCV throughout the world, as well as in populations, ages, risk factors and disparities in the costs of drugs and the availability of funds will make reaching this goal difficult.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C elimination – Macro‐elimination

Kåberg

Weiland

2020

Liver International

View full text Add to dashboard Cite

In 2016 the WHO set a goal to obtain an 80% reduction in new chronic HCV cases, requiring a level of diagnosis of 90%, treatment coverage of 80% and resulting in a 65% reduction in HCV‐related deaths by 2030. This goal is easier to reach in specific populations such as people who inject drugs (PWID), men who have sex with men (MSM) or blood‐transfusion recipients before screening for HCV became mandatory and in high‐income regions. It is much more difficult to achieve macro‐elimination throughout the population especially in low‐income areas with underdeveloped infrastructures, a high prevalence of HCV and limited economic resources. To achieve the WHO goals by 2030, awareness of HCV must increase and the cascade of care must be improved and implemented. Diagnostic procedures and treatment should be affordable and universally available. At the end of 2017 fewer than 15 countries were on track to reach these goals by 2030.

show abstract

Is global elimination of HCV realistic?

Cited by 40 publications

References 62 publications

Milestones in the pathogenesis and management of primary liver cancer

Milestones in the pathogenesis and management of primary liver cancer

Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment

Hepatitis C elimination – Macro‐elimination

Contact Info

Product

Resources

About